Document is current
Any future updates will be listed below
-
Authors
Li, Shuzhan
Qin, Jing
Sun, Qian
Zhao, Hua
Xiong, Yanjuan
Wang, Yang
Han, Ying
Zhang, Jiali
Zhang, Weihong
Shen, Meng
Yang, Fan
Ren, Baozhu
Zhou, Li
Li, Runmei
Hui, Zhenzhen
Tian, Xiao
Cao, Shui
Du, Weijiao
Yu, Wenwen
Liu, Liang
Zhang, Xinwei
Ren, Xiubao
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03987698 at ClinicalTrials.govDocuments that mention this clinical trial
Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma
https://doi.org/10.1038/s41598-026-38881-1
-
Funding
Funding for this research was provided by:
Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-009A)
National Natural Science Foundation of China (82373283)
National Natural Science Foundation of China (82302913)
National Natural Science Foundation of China (82372779)
NSFC Cultivation Program of Tianjin Medical University Cancer Institute & Hospital (230103)
The Science & Technology Development Fund of Tianjin Education Commission for Higher Education (2021KJ203)
Doctor Startup Fund of Tianjin Medical University Cancer Institute and Hospital (B2414)
- License Information
-
More Information
Article History
Received: 6 October 2025
Accepted: 31 January 2026
First Online: 7 February 2026
Declarations
:
: The authors declare no competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Tianjin Medical University Cancer Hospital and Institute (No. E2017232). All patients provided written informed consent for their involvement and for the publication of the results.
: The authors affirm that participant provided informed consent for publication of the images in Fig. 5A, B and C and Figure .
: Informed consent was obtained from all individual participants included in the study.
